Patient-Focused, Compassionate Clinical Trials
At Jus-Biotech, we recognize that clinical studies in the biotechnology sphere frequently involve patients with extensive, often systemic medical and genetic challenges that can present a family crisis. We ensure that our expert advisors -- who have decades of experience advancing therapeutic agents to market in multiple categories -- assist our clients in conducting compassionate investigatory studies that deeply engage patients and caregivers.
Jus-Biotech Facilitates Secure Communication
Our patented and unprecedented Jus-Biotech expert advisory and Apple-approved and Android-compatible technology platform gleans highly accurate data by advancing fully secure, timestamped, blockchain and permissions-based communication within a study.
Jus-Biotech ensures patient confidentiality is never compromised while enabling greater patient engagement than ever before across desktop, tablet and smartphone devices. We ensure accuracy by securely advancing communication between patients and clinicians, and clinicians and the C-suite, to provide an up-to-the-moment transparent 360-degree view of all activities and interactions within a study, leading to better patient communication, a more accurate data set and enterprise-wide decision-making. Further, our Open Forum enables patients and trial staff to pose questions and gain clarity on instructions and responsibilities leading to a more successful study result.
From the initial application through the pre-clinical stage, to the clinical trial phases and FDA approval, the Jus-Pharma app we created for use by our pharmaceutical and biotech clients alike optimizes ROI, preserves capital, protects investors and mitigates litigation and safety risks while advancing efficiency in communication. Jus-Pharma is also a network that tracks, audits, and stores all documents, data and communications associated with a clinical trial. It facilitates secure text/voice/video communication/digital and voice signatures utilizing blockchain features between executives, researchers and participants.
We Protect Resources and Enterprise Valuation
Jus-Biotech is Expert Advisory on Demand
Our intensive, success-focused Jus-Biotech paradigm offers expert advisory on demand at every step of a clinical trial: it permits biotech enterprises to conduct complex, multi-site clinical studies that result in drug and device approval while optimizing resource allocation.
For Start-Ups and Legacy Companies Alike
Jus-Biotech is the expert advisory and hyper-secure technology platform that empowers start-up companies and long-established legacy companies in the biotech sphere to deliver effective, secure clinical trials that accelerate commercialization of the most transformative therapeutic interventions across all categories.
All biotech organizations, large and small, new or decades-old, can innovate faster with our unrivaled platform of expert advisory from pre-clinical through market introduction. Jus-Biotech empowers the biotechnology and life sciences industry to save and improve more lives more quickly while advancing their market value, overall profitability and capability to continue to innovate.
With Jus-Biotech, we help both long-established and emerging biotech companies reach their drug and device development and commercialization objectives while preserving capital and appropriating resources only to therapeutic agents with the highest likelihood of advancing to market and having an enduring positive impact on global wellness.
Our Jus-Biotech Team
Our scientific, clinical, regulatory, regulatory, legal, technical and business experts have a combined experience of more than 100 years in advancing scientific and clinical innovations, mitigating financial and legal risks and speeding to market an array of medications, medical devices, vaccines and other therapeutic agents across numerous categories. We are a partner to the most innovative biotech companies to bring to market a universe of therapeutic interventions with a lasting impact on global wellness and human sustainability.
Our unparalleled advisory illuminates challenges early, identifies therapeutic opportunities and mitigates risk. We are a partner to the most innovative biotech companies to bring to market a universe of therapeutic interventions with a lasting impact on global wellness and human sustainability.
Beatrice O’Brien brings immeasurable value to JusLaw, not just her passion for the Law and the Legal Industry but also her over 20 years of legal experience with Wall Street Firms, such as, Cadwalder Wickersham & Taft and with international firms in Australia and the UK.
She has worked with high profile clients, such as, Warren Buffet and on high-profile cases, such as, the largest reorganization and restructuring cases in US, UK, and Australian corporate history.
Beatrice is a graduate of Bond University the only Private Law School in Australia with a Law Degree and is a graduate of Harvard Law School Executive Program. She speaks fluent Hindi. Beatrice leveraged her extensive experience to create the first of its kind marketplace revolutionizing the legal industry.
John C. Ferrara
John C. Ferrara is on the Advisory Board of JusLaw with extensive experience in corporate governance, business strategy, finance, operations, business development, capital raising, risk management, cash management, M&A and company exits.
John has served on the Boards of four (4) public companies; including GAMCO Investors, Inc. (NYSE:GBL) and has been the CFO of several public companies; including The Street Inc. (NASDAQ:TST), EDGAR Online, Inc.(NASDAQ:EFGR) and Renaissance Communications Corp. (NYSE:RRR).
John has over twenty years of C-level experience at public, private and PE portfolio entrepreneurial companies; including start-ups, turnarounds, and high growth organizations, with a prior background at two Fortune 500 corporations (NBC & American Express) and a Big 4 public accounting firm (Deloitte).
ADVISORY BOARD MEMBER
Partner with McKinsey & Company for over 20 years, based out of Hong Kong & Tokyo. Oliver brings to JusLaw over 20 years international experience in strategy and business development and start-ups. He is a graduate of Oxford & Harvard Business School.
Mr. Ramsbottom speaks fluent Mandarin.
Duane Lakings delivers a broad array of expertise in various primary areas of drug discovery and development to the JusGlobal enterprise. Dr. Lakings is experienced across nonclinical pharmacology, pharmacokinetics and toxicology as well as clinical safety, efficacy, chemistry, manufacturing and control of drug substances and proposed drug products and regulatory affairs. He assists pharmaceutical and biotechnology companies in evaluating results from their drug discovery and development programs, including document preparation, protocol design and implementation across multiple disciplines, as well as further evaluation of drug candidates to support regulatory submission.
Dr. Lakings has served as president of Texas-based Drug Safety Evaluation and was director of drug safety evaluations at Regeneron Pharmaceuticals in Tarrytown, New York as well as a senior research investigator II at BMS-PRI (Princeton, NJ). He has been a research scientist at The Upjohn Company in Michigan and he has conducted research for the National Cancer Institute and the University of Missouri-Columbia.
Dr. Lakings has extensive publishing credits. He has authored or co-authored 44 refereed papers and 150 company-specific papers, nine book chapters on drug development, 26 abstracts for oral/poster presentation, eight commissioned drug candidate evaluation reviews and a 300-page report on biological contract research organizations (CROs).
Dr. Eyal Ron adds value for Jus Pharma clients in the pharmaceutical, biotechnology and medical device space by accelerating the timeline toward the value inflection point. Dr. Ron delivers an entrepreneurial thought process coupled with science-based evaluation to enhance the overarching enterprise value regarding product candidates, without creating a need for costly infrastructure to foster growth.
With three decades of experience in the development of drugs, biomaterials, devices and drug delivery systems, Dr. Ron has become known for combining science with sound business strategy, making him an ideally qualified expert on the JusGlobal team. He developed and implemented the scientific, regulatory and clinical strategy for several companies. Dr. Ron offers extensive depth in the total therapeutic development process including project management, clinical trials, regulatory compliance and approval, drug delivery systems, quality control and scale-up. Dr. Ron has authored more than 100 papers, book chapters and abstracts. He is also the inventor of 50 patents, principally in drug formulations, drug delivery, tissue engineering and biomaterials.
He has been a founder or principal formulator of biotech companies, bringing seven new medications to market. He has held the position of COO, CTO and CSO, director of pharmaceutical development and principal investigator at several pharmaceutical and biotech firms.
Dr. Ron received a PhD from Brandeis University and has completed post graduate study at Massachusetts Institute of Technology. He earned a BS at Tel Aviv University.
Dr. Evan Siegel, Ph.D.
CHIEF REGULATORY OFFICER
Dr. Evan Siegel adds value for Jus- Pharma clients in the pharmaceutical, biotechnology and medical device space in the Regulatory Affairs and Product Development.
Dr. Siegel served as Chief Executive Officer of OXO Chemie Inc. from 1997 to 1999. Before he joined OXO Chemie, he was the Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc. Prior to that he was Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., in Research Triangle Park, North Carolina. He has served in regulatory affairs and executive positions in the pharmaceutical (Astra, Syntex, and OXO Chemie), Genetics Testing Industries (Medical Science Systems); and trade association environments.
Dr. Siegel has also held positions as a Toxicology Reviewer at the US Food and Drug Administration and California Department of Health Services and, at the latter, was Chief of Special Services.
He attended Bucknall University where he received a Bachelor’s of Science degree in Physics; Rutgers University, where he earned a Masters of Science degree in Radiological Health/Health Physics; the Waksman Institute of Microbiology where he earned both his Masters and Doctor of Philosophy degrees in Virology and Molecular Biology, and was awarded Postdoctoral Fellowships in Medical Genetics and Genetics Counselling at the University of North Carolina at Chapel Hill.
Dr. Siegel is an Adjunct Professor at the University of Queensland and the Centre for the Study of Preclinical Drug Development, Brisbane, Australia, and a member of the California Lieutenant Governor’s Biotechnology Advisory Group to the California Council for Economic Development.
Patricia Blaine is a registered respiratory therapist, university instructor and accomplished medical writer. She has served as a consultant in clinical trial protocols for leading pharmaceutical companies such as Eisai, Daiichi Sankyo, Forest Laboratories and Schering-Plough.
Ms. Blaine has been a senior director of medical writing and a staff medical writer for Oxford Research, Corning-Besselaar and Schering-Plough. She has been director of clinical education at the University of Medicine and Dentistry of New Jersey (UMDNJ). Ms. Blaine provided medical writing for a poster presented at a psychiatric conference focusing on a Phase IV multi-site investigatory study on carmbamazepine.
Patricia Blaine earned a Master’s degree in Education with a concentration in Allied Health Education from Rutgers University and a Bachelor of Arts in Psychology and English from Seton Hill University (Pennsylvania).